Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Dec 18;20(1):28–55. doi: 10.1038/s44320-023-00004-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. Creative Commons Public Domain Dedication waiver http://creativecommons.org/publicdomain/zero/1.0/ applies to the data associated with this article, unless otherwise stated in a credit line to the data, but does not extend to the graphical or creative elements of illustrations, charts, or figures. This waiver removes legal barriers to the re-use and mining of research data. According to standard scholarly practice, it is recommended to provide appropriate citation and attribution whenever technically possible.

PMC Copyright notice

(A) Activity landscapes of sarcoma lines (right panel) computed from the proteomic data based on the intensities of the molecular features shown in the left panel (see “Methods” for details). (B) Distribution of activity scores of protein in G401 and HT1080 cells showing differences in activity scores for FGFR and PDGFRB. (C) Relative viability (AUC) of sarcoma cell lines in response to four FGFR inhibitors. (D) Left panel: list of kinases ranked by activity score in SW684 cells. The asterisk denotes a kinase that is a target of the most potent kinase inhibitor. Right panel: relative sensitivity of SW684 cells to all drugs in the screen. (E) Left panel: same as panel (D) but for KHOS-NP cells. Middle panel: dose–response curves for the phase I/II inhibitors CYC-116 and PF-3758309 (the gene names of the targets of the drugs are indicated in parenthesis). Measurements were in technical triplicates and error bars denote the standard deviation (SD). Right panel: relative sensitivity of KHOS-NP cells to all drugs in the screen. Source data are available online for this figure.